JPRN-UMIN000009611已完成1 期
Phase I Clinical Study of Combination Therapy with Eribulin and Capecitabine in Patients with Progressive Recurring Breast Cancer(JBCRG-18Cape) - JBCRG-18Cape
JBCRG (Japan Breast Cancer Research Group)0 个研究点目标入组 9 人开始时间: 2012年12月26日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
Results One patient had grade 4 DLTs at level 0 (Cr 7.65 mg/dL and UA 13.4 mg/dL), considered associated with study drugs. Level 1 dosing was taken as the RD. Of three patients in level 1, one achieved PR and one had prolonged SD. Conclusions Eribulin with capecitabine in the level 1 dosing schedule was associated with manageable toxicities and promising clinical activity. This combination is recommended for phase II investigation.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Patients who were administered with capecitabine in the treatment immediately prior to this clinical study. 2) Patients with coexisting infection or cases with pyrexia suspected of infection. 3) Patients with serious drug allergy. 4) Patients with serious renal disorder and hepatic disorder (jaundice). 5) Patients with clear indications of interstitial pneumonia or pulmonary fibrosis in chest X-ray. 6) Patients with large pleural/peritoneal effusion (patients required drainage) 7) Patients with poorly-controlled hypertension and diabetes mellitus. 8) Patients with continuous systemic administration (oral or intravenous) of steroid. 9) Pregnant patients or cases with possible pregnancy. 10) Patients with active multiple primary cancer. 11) Cases with preexisting condition of psychiatric disorder or central nervous system disorder. 12) Patients with active brain metastasis. 13) Patients participating in other clinical study. 14) Cases that the investigator (subinvestigator) judged as inappropriate as the subject of this clinical study. 15) Patients with hepatitis B antibody.
研究者
相似试验
已完成
1 期
Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with oral fluorinated pyrimidine compound S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancerPatients with gemcitabine-refractory metastatic pancreatic cancerJPRN-C000000450ational Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division40
进行中（未招募）
不适用
Estudio del tratamiento combinado, en primera línea, de capecitabina administrada de forma continua, oxaliplatino y bevacizumab administrado bisemanalmente en pacientes con adenocarcinoma colorrectal metastático o avanzado.Adenocarcinoma colorrectal metastásico.EUCTR2005-006171-12-ESnidad Integral de Investigación en Oncología S.L.
已完成
不适用
Phase I clinical study of a combined modality treatment of sarcomas of the extremities or in head and neck area with radiotherapy (RT) and dose-escalation of Pazopanibsoft tissue tumor10028389sarcomaNL-OMON39288ederlands Kanker Instituut15
已完成
不适用
The phase I clinical study about the combined therapy, high purity natural killer (NK) cell therapy and IgG1 antibody to inoperable advance and recurrence digestive cancerJPRN-UMIN000013378Kyoto Prefectural University of Medicine9
招募中
1 期
Phase 1 clinical study on the combination therapy of CHP-NY-ESO-1 cancer vaccine and Poly-ICLC for the treatment of patients with NY-ESO-1 expressing refractory esophageal cancerRefractory esophageal cancerJPRN-UMIN000007961Kyoto Prefectural University of Medicine18